The reference company in the field of Valencian biotechnology ADM Biópolis, located in the innovation business ecosystem in the University of Valencia Science Park (PCUV), continues on its growth path. This is reflected in the company's accounts deposited at the Mercantile Registry, which accompanied the good results in its activity with an entry into profits. In the last fiscal year presented, its turnover soared to 12.9 million euros, 87% more than the previous year, specifically, the company earned 285,660 euros in 2022. After closing the 2021 financial year with a loss of half a million euros, its growth is currently supported by its merger with Lifesequencing, a division of Archer Daniels Midland (ADM), and by the opening of a pioneering plant in the Valencian municipality of Carcaixent, which has an investment of 30 million euros, enabling it to increase its production capacity fivefold.
The company, majority-owned by the US multinational ADM, is focused on the production of probiotics, enzymes, proteins and other additives for different industries, and is also the R&D flagship within the investment group, particularly in the area of microbiome and health. The probiotics and post-biotics produced at ADM Biópolis are used in the dietary supplement industry, in the food and beverage industry, and also in applications for pets and animal welfare.
In the last fiscal year presented, its turnover soared to 12.9 million euros, 87% more than the previous year, specifically, the company earned 285,660 euros in 2022
The new ADM Biópolis plant in the Valencian municipality of Carcaixent. PHOTO: ADM Biópolis.
New plant in Carcaixent
The company, led by Daniel Ramón, emphasizes its reinforcement of scientific and innovation capacity, providing the company with the "most modern and disruptive" research equipment in laboratories and pilot plants, and supported by the construction of the new plant in Carcaixent, which has 2,400 square meters, where it is expected to achieve a yield of 50 tons of product per year from 2026, reaching the maximum production capacity. "The objective of ADM Biópolis is to continue creating science and technological leadership in the study of the microbiome to develop and produce nutritional solutions of proven efficacy through clinical studies, which improve the health and well-being of consumers," they emphasize in the report presented.
"ADM Biópolis' goal is to continue to create science and technological leadership in the study of the microbiome to develop and produce nutritional solutions with proven efficacy through clinical studies that improve the health and well-being of consumers."
U.S. and Asia, growing
The company continues to expand internationally, opening new markets and consolidating existing ones. The United States and China stand out as the main markets. Meanwhile, the Spanish market has lost percentage weight in its turnover due to the increase in exports and, at the end of the year, represented only 8.7% of its sales. The rest is distributed among 14 other countries.
During 2022, revenues from research and development services provided to customers continued to decline. A reduction aligned with its strategy that the Microbiome R&D Platform, created at Biópolis, should focus on supporting internal scientific and technological development for ADM, both for ADM and other group companies. Even so, according to the management report, ADM Biópolis continues to provide external R&D services, but only in strategic collaboration projects with key clients and, in most cases, linked to ingredient sales projects.
News in the media